CVE-2026-34323

CVE-2026-34323 is a medium-severity vulnerability in Oracle Life Sciences Inform with a CVSS 3.x base score of 6.3. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-284.

Key facts

Description

Vulnerability in the Oracle Life Sciences InForm product of Oracle Life Science Applications (component: IDM Authentication). Supported versions that are affected are 7.0.1.0 and 7.0.1.1. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences InForm. Successful attacks require human interaction from a person other than the attacker. Successful attacks of this vulnerability can result in unauthorized update, insert or delete access to some of Oracle Life Sciences InForm accessible data as well as unauthorized read access to a subset of Oracle Life Sciences InForm accessible data and unauthorized ability to cause a partial denial of service (partial DOS) of Oracle Life Sciences InForm. CVSS 3.1 Base Score 6.3 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:L).

Frequently asked questions

What is CVE-2026-34323?
Vulnerability in the Oracle Life Sciences InForm product of Oracle Life Science Applications (component: IDM Authentication). Supported versions that are affected are 7.0.1.0 and 7.0.1.1. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences InForm. Successful attacks require human interaction from a person other than the attacker. Successful attacks of this vulnerability can result in unauthorized update, insert or delete access to some of Oracle Life Sciences InForm accessible data as well as unauthorized read access to a subset of Oracle Life Sciences InForm accessible data and unauthorized ability to cause a partial denial of service (partial DOS) of Oracle Life Sciences InForm. CVSS 3.1 Base Score 6.3 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:L).
How severe is CVE-2026-34323?
CVE-2026-34323 has a CVSS 3.x base score of 6.3, rated medium severity. It is exploitable over network with low attack complexity, requires no privileges and user interaction. Impact on confidentiality is low, integrity low, and availability low.
Is CVE-2026-34323 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (7th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2026-34323?
CVE-2026-34323 primarily affects Oracle Life Sciences Inform. In total, 2 product configurations (CPEs) are listed as vulnerable; see the affected-products list for the exact versions.
How do I fix CVE-2026-34323?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
Does CVE-2026-34323 have an EU (EUVD) identifier?
Yes. CVE-2026-34323 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2026-24426.
When was CVE-2026-34323 published?
CVE-2026-34323 was published on 2026-04-21 and last updated on 2026-06-17.

References

Affected products (2)

More vulnerabilities in Oracle Life Sciences Inform

All CVEs affecting Oracle Life Sciences Inform →

Other CWE-284 (Improper Access Control) vulnerabilities

Browse all CWE-284 (Improper Access Control) vulnerabilities →